The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat?

Mariona Riudavets; David Planchard

doi:10.4143/crt.2024.714

The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat?: Mariona Riudavets¹ , David Planchard²; DOI: https://doi.org/10.4143/crt.2024.714 [Accepted]
Published online: November 28, 2024

¹Department of Pneumology, Hôpital Cochin APHP Centre, Paris, France
²Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France

Corresponding author: David PlanchardEmail: David.PLANCHARD@gustaveroussy.fr

Received: 26 July 2024 • Accepted: 27 November 2024

3,011 Views
44 Download
0 Crossref
0 Scopus

Abstract

Antibody Drug Conjugates (ADCs) are a novel class of therapeutics that structurally are composed by an antibody directed to a tumour epitope connected via a linker to a cytotoxic payload, and that have shown significant antitumor activity across a range of malignancies including lung cancer. In this article we review the pharmacology and design of ADCs, as well as we describe the results of different studies evaluating ADCs in lung cancer directed to several targets including HER2, HER3, TROP2, MET, CEACAM5 and DLL3, among others.

Keywords: Lung neoplasms, ADCs, HER2, HER3, TROP2, MET, CEACAM5, DLL3

Figure & Data

References

Citations

Citations to this article as recorded by

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.